Glioblastoma
900
156
253
356
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
154 trials with published results (17%)
Research Maturity
356 completed trials (40% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.2%
110 terminated out of 900 trials
76.4%
-10.2% vs benchmark
6%
50 trials in Phase 3/4
43%
154 of 356 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 356 completed trials
Clinical Trials (900)
Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Immune Response in Glioblastoma: A Kinetic Analysis of Immune Biomarkers.
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
Oral Gallium Maltolate for Recurrent Glioblastoma
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Pharmacoscopy for Patients With Refractory Primary Brain Tumors